Cas cliniqueUlcérations buccales après prise de mycophénolate de sodium (Myfortic®)
Références (16)
- et al.
Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients
Am J Transplant
(2004) - et al.
Comparison of enteric-coated mycophenolate sodium with mycophenolate mofetil in living renal allograft transplantation
Transplantation Proceedings
(2006) - et al.
Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: results of a 12 month multicenter, open-Label, prospective Study
Transplantation Proceedings
(2006) Adverse gastrointestinal effects to mycophenolate mofetil aetiology, incidence and management
Drug Saf
(2001)- et al.
The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation
Clin Transplant
(2003) - et al.
Lymphocyte selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice
Scand J immunol
(1991) - et al.
Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link?
Drug Saf
(2001) - et al.
Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation
J Am Soc Nephrol
(2003)
Cited by (8)
Cutaneous Toxicities From Transplantation-Related Medications
2017, American Journal of TransplantationBilateral palatal ulcers in a patient on immunosuppressive therapy
2016, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyCitation Excerpt :In their discussion, the authors also speculated that previous reports of methotrexate-induced oral ulcers, which were not accompanied by pathologic assessment,17,18 might actually have represented cases of EBVMCU. We think the same can be applied to the reports of oral ulcers induced by mycophenolate mofetil1 and mycophenolate sodium,2 as biopsy of the lesions was not performed in either case. Since Dojcinov et al.’s article was published, several other case reports of EBVMCU have emerged to describe patients having various states of immunosuppression.
Mycophenolate mofetil-induced oral ulcerations in solid organ transplant recipients: A report of 3 cases
2015, JAAD Case ReportsCitation Excerpt :This hypothesis is substantiated by the observation that in each reported case of MMF-associated ulcers (including the 3 published in this case series), both the size of the ulcers and their associated pain and odynophagia markedly diminished immediately after the discontinuation of MMF therapy, suggesting a direct toxigenic relationship between the 2. Moreover, a case report published by Miquel et al11 describing the association of oral ulcers and mycophenolate sodium (an enteric-coated, delayed-release formulation of MMF) in a patient with systemic lupus erythematosus documented the abrupt recurrence of the patient's oral ulcers several days after she was rechallenged with mycophenolate sodium, further corroborating the direct toxicity hypothesis. Second, some have posited that the association between MMF and oral ulcers may be owing to viral infection secondary to immunosuppression.
Oral ulcerations as a sequela of tacrolimus and mycophenolate mofetil therapy
2014, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyCitation Excerpt :Oral ulcers also have been recognized as an occasional complication of both mycophenolate mofetil and tacrolimus.2,4,10-12 Although mycophenolate mofetil has been implicated in multiple cases, there is only 1 report of a direct link between the 2.10-12 Far less incidence of oral ulcerations from tacrolimus has been reported.2,4
Mycophenolate-induced oral ulcers: Case report and literature review
2020, American Journal of Health-System Pharmacy